Virpax Pharmaceuticals, Inc. VRPX
Set alert
At close · Oct 30
After hours · Oct 30, 5:00 PM ET
- YTD
- -92.79%
- 1 year
- -96.19%
- Open
- 0.021
- Prev close
- 0.0008
- Mkt cap
- 994
- Vol
- 51
- Avg vol
- 311
- EPS
- -5.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.021
- High
- 0.021
- Forward P/E
- -0.38
- Beta
- 1.09
- Short ratio
- 1.04
- Inst. own
- 1.90%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.54406
- 200-d avg
- 1.40
- 1y target
- 3.00
Key statistics
- Market cap
- 2.78M
- Enterprise value
- 1.13M
- Trailing P/E
- 0.00
- Forward P/E
- -0.38
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.21
- EPS (TTM)
- -7.24
- Beta
- 1.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.98M
- Total cash
- 1.87M
- Total debt
- 0
- Return on equity
- -362.29%
- Shares outstanding
- 8.09M
- Short % of float
- 7.65%
- 50-day average
- 0.54406
- 200-day average
- 1.40
Analyst view
Consensus: none
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.43 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -1.75 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -2.75 | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | -5.10 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -2.70 | — | — |
| May 12, 2023 | Mar 1, 2023 | 0.00 | -1.30 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2024 | Maxim Group | down | Buy | Hold |
| Jul 19, 2024 | Maxim Group | up | Hold | Buy |
| May 22, 2024 | Maxim Group | down | Buy | Hold |
About Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- virpaxpharma.com
News
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
- Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on VRPX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 0.39% | 31,382 | 10.79K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.35% | 27,971 | 9.62K | Sep 29, 2024 |
| UBS Group AG | 0.25% | 20,435 | 7.03K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.15% | 12,522 | 4.31K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.05% | 3,837 | 1.32K | Sep 29, 2024 |
| Signature Resources Capital Management, LLC | 0.00% | 50 | 17 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.31% | 25,474 | 8.76K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 8,756 | 3.01K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.08% | 6,629 | 2.28K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 6,857 | 2.36K | Oct 30, 2024 |